ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1515000
Clinical Manifestations, Diagnostic Criteria, and Treatment Outcomes of Minocycline-Associated DRESS Syndrome: A Comprehensive Exploration of Published Cases
Provisionally accepted
- 1Fuda Cancer Hospital, Guangzhou, Guangdong Province, China
- 2Ganzhou People's Hospital, Ganzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Minocycline can induce a rare but serious adverse drug reaction known as drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. We explored the clinical features of minocycline-associated DRESS to aid in early diagnosis and risk mitigation. Methods: A comprehensive exploration of published cases from the start of electronic databases (PubMed, Embase, Web of Science, CNKI, Wanfang Data) to December 1, 2024. Cases were screened using RegiSCAR criteria. Results: A total of 3928 citations were identified through database searches, and after screening, 39 case reports (comprising 57 patients) were included. Fifty-seven patients (mean age 37.1 years) exhibited median DRESS onset at 17.5 days. Respiratory symptoms (87.7%, n=50) dominated, including non-productive cough, dyspnea, pharyngitis, and wheezing. Fever occurred in 45 (78.9%) patients. Median eosinophilia peaked at 4.09×10⁹/L. Symptom improvement median time was 10.5 days. Overall, forty-five patients (93.8% of 48 with outcome data) recovered postminocycline discontinuation. Four deaths occurred (hepatic failure, refractory hypotension, unknown causes). Conclusions: Minocycline-associated DRESS syndrome is characterized by diverse clinical manifestations, including prominent respiratory symptoms. Timely drug cessation, corticosteroid therapy, and vigilant monitoring are critical to optimize outcomes. These findings underscore the need for enhanced pharmacovigilance in high-risk populations.
Keywords: Minocycline, Eosinophilia, Hypersensitivity, dress, Adverse event
Received: 22 Oct 2024; Accepted: 09 Jul 2025.
Copyright: © 2025 Pan and WU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: QIQUAN WU, Ganzhou People's Hospital, Ganzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.